Welcome to our dedicated page for Monogram Orthopaedics news (Ticker: MGRM), a resource for investors and traders seeking the latest updates and insights on Monogram Orthopaedics stock.
Monogram Technologies Inc. (formerly Nasdaq: MGRM) generated news as an AI-driven orthopedic robotics company focused on total knee arthroplasty and patient-optimized implants. Company press releases and SEC filings highlight developments in robotic-assisted surgery, regulatory milestones, clinical trials and corporate transactions, including its acquisition by Zimmer Biomet.
News coverage for Monogram has emphasized progress with its mBôs TKA System and mPress implants. The company announced FDA 510(k) clearance for the Monogram mBôs TKA System, allowing it to market the device subject to the Federal Food, Drug, and Cosmetic Act. Monogram also reported FDA clearance for its mPress implants and described plans to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables and other instrumentation necessary for reconstructive joint replacement procedures.
Another key stream of news involves Monogram’s clinical and international activities. The company disclosed that India’s Central Drugs Standard Control Organization approved import of the mBôs TKA system for a 102-patient, multi-center clinical investigation in collaboration with Shalby Limited, described as one of the world’s largest orthopedic hospital groups. In July 2025, Monogram announced what it called the world’s first fully autonomous saw-based robotic knee replacement surgery on a live patient, performed at Krishna Shalby Hospital in Ahmedabad, India, as part of this trial.
Corporate and capital markets updates have also been central to MGRM-related news. Monogram reported financing-related actions such as the mandatory conversion of its 8.00% Series D Convertible Cumulative Preferred Stock after a specified trading condition was met. In July 2025, Zimmer Biomet and Monogram jointly announced a definitive agreement for Zimmer Biomet to acquire all outstanding shares of Monogram, with additional details provided in subsequent SEC filings and communications to shareholders. Later, an October 2025 Form 8-K confirmed completion of the merger, after which Monogram became a wholly owned subsidiary of Zimmer Biomet and its common stock was delisted from Nasdaq.
Investors and observers reviewing the MGRM news feed can therefore expect historical updates on robotic knee surgery milestones, regulatory clearances, international clinical trials, preferred stock actions, and the sequence of events leading to the Zimmer Biomet acquisition and delisting of the MGRM ticker.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.